“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, Baltimore, April 1, 2015: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin
Pharmaceuticals Inc. (collectively Lupin) yesterday has launched its Amlodipine and Valsartan Tablets, 5 mg/160
mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis
Pharmaceuticals Corporation’s Exforge® tablets 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320mg
strengths. Lupin had received final approval from the United States Food and Drug Administration (FDA) for the
Lupin’s Amlodipine and Valsartan Tablets is the combination tablet of Amlodipine, a dihydropyridine calcium
channel blocker (DHP CCB) and Valsartan, an angiotensin II receptor blocker (ARB). Lupin’s Amlodipine and
Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure:
Exforge® Tablets had U.S sales of US$ 414.9 million (IMS MAT December, 2014).
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of
branded and generic formulations as well as biotechnology products and APIs globally. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space
and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions,
IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top
10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014,
Lupin's Consolidated revenues and Profit after tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364
million (USD 304 million) respectively. Please visit http://www.lupin.com for more information.
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.
About Lupin Pharmaceuticals Inc.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality,
affordable generic medicines and branded formulations trusted by healthcare professionals and patients across
geographies. For more information, please do visit http://www.lupinpharmaceuticals.com
You could also follow us on Twitter – www.twitter.com/lupinlimited
For more information, please contact –
Head – Corporate Communications
Ph: +91-22- 98 20 338 555
Head – M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement